BiomX Reports $19.1 Million Net Loss and Strategic Shift to Defense Sector

BiomX Inc. reported a significant financial downturn in its latest quarterly filing, with a net loss of $19.1 million for the three months ending March 31, 2026, compared to a loss of $7.7 million during the same period in 2025. The company's operating loss also increased to $1.3 million from $7.8 million year-over-year. The increase in losses is attributed to a combination of factors, including substantial expenses related to the company's strategic transition and the impact of its recent acquisitions. The basic and diluted loss per share rose to $7.38, up from $6.27 in the previous year, reflecting a higher weighted average number of shares outstanding due to recent equity transactions.

In terms of liquidity, BiomX's cash and cash equivalents decreased to $1.2 million as of March 31, 2026, down from $4.4 million at the end of 2025. The company’s total assets also fell to $3.3 million from $5.8 million, primarily due to the deconsolidation of a subsidiary and increased liabilities. Current liabilities decreased to $2.4 million from $6.4 million, while non-current liabilities rose to $1.7 million from $706,000, largely due to the revaluation of warrants. The accumulated deficit increased to $236 million, indicating ongoing financial challenges.

Strategically, BiomX has shifted its focus from biopharmaceuticals to the defense and security sectors, following the discontinuation of its Phase 2b clinical trial for phage therapy. The company has made significant organizational changes, including the appointment of a new Chief Financial Officer and Chief Executive Officer in early 2026. Additionally, BiomX has expanded its operations through the acquisition of 60% of Dr. Frucht Systems Ltd. and Zorro Net Ltd., as well as the establishment of a new subsidiary, X Security & Defense Ltd. These moves are part of a broader strategy to enter the defense and critical infrastructure technology markets.

Operationally, the company has faced challenges due to geopolitical instability in Israel, where it is based. The ongoing conflict has raised concerns about the potential impact on business operations and employee availability. Despite these challenges, BiomX is optimistic about generating revenue from its new subsidiaries, with expectations of initial revenues beginning in the second quarter of 2026. However, the company acknowledges that its ability to continue as a going concern is uncertain, contingent on its capacity to raise additional capital and the success of its new business ventures.

Looking ahead, BiomX plans to fund its operations through various means, including equity and debt offerings. The company is actively working to regain compliance with NYSE American listing requirements and is focused on stabilizing its financial position. Management has expressed cautious optimism regarding the future, contingent on the successful integration of its new subsidiaries and the overall market conditions in the defense sector.